[English] 日本語
Yorodumi- EMDB-45972: SARS-CoV-2 BA.2.86 Spike trimer in complex with TRI2-2 minibinder -
+
Open data
-
Basic information
| Entry | ![]() | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Title | SARS-CoV-2 BA.2.86 Spike trimer in complex with TRI2-2 minibinder | |||||||||
Map data | sharpened map | |||||||||
Sample |
| |||||||||
Keywords | Sarbecoviruses / Spike glycoprotein / Structural Genomic / inhibitor / viral protein / minibinder / Structural Genomics / Seattle Structural Genomics Center for Infectious Disease / SSGCID | |||||||||
| Biological species | Sarbecovirus sp. / ![]() | |||||||||
| Method | single particle reconstruction / cryo EM / Resolution: 2.4 Å | |||||||||
Authors | Lee J / Veesler D / Seattle Structural Genomics Center for Infectious Disease (SSGCID) | |||||||||
| Funding support | United States, 1 items
| |||||||||
Citation | Journal: Commun Biol / Year: 2026Title: The computationally designed TRI2-2 miniprotein inhibitor protects against multiple SARS-CoV-2 Omicron variants. Authors: Jimin Lee / James Brett Case / Young-Jun Park / Rashmi Ravichandran / Daniel Asarnow / M Alejandra Tortorici / Jack T Brown / Shilpa Sanapala / Lauren Carter / David Baker / Michael S Diamond / David Veesler / ![]() Abstract: The continued evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has compromised neutralizing antibody responses elicited by prior infection or vaccination and abolished the ...The continued evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has compromised neutralizing antibody responses elicited by prior infection or vaccination and abolished the utility of most monoclonal antibody therapeutics. We previously described a computationally-designed, homotrimeric miniprotein inhibitor, designated TRI2-2, that protects mice against pre-Omicron SARS-CoV-2 variants. Here, we show that TRI2-2 exhibits broadly neutralizing activity of SARS-CoV-2 variants and protects mice against BQ.1.1, XBB.1.5 and BA.2.86 challenge when administered intranasally post-exposure. The resistance of TRI2-2 to viral escape by most variants and the ability to deliver it directly to the upper airways highlight the potential of the multivalent miniprotein inhibitor as an alternative therapeutic modality. | |||||||||
| History |
|
-
Structure visualization
| Supplemental images |
|---|
-
Downloads & links
-EMDB archive
| Map data | emd_45972.map.gz | 484.1 MB | EMDB map data format | |
|---|---|---|---|---|
| Header (meta data) | emd-45972-v30.xml emd-45972.xml | 22.6 KB 22.6 KB | Display Display | EMDB header |
| Images | emd_45972.png | 72.5 KB | ||
| Filedesc metadata | emd-45972.cif.gz | 6.9 KB | ||
| Others | emd_45972_additional_1.map.gz emd_45972_half_map_1.map.gz emd_45972_half_map_2.map.gz | 258.5 MB 475.9 MB 475.9 MB | ||
| Archive directory | http://ftp.pdbj.org/pub/emdb/structures/EMD-45972 ftp://ftp.pdbj.org/pub/emdb/structures/EMD-45972 | HTTPS FTP |
-Validation report
| Summary document | emd_45972_validation.pdf.gz | 769.4 KB | Display | EMDB validaton report |
|---|---|---|---|---|
| Full document | emd_45972_full_validation.pdf.gz | 768.9 KB | Display | |
| Data in XML | emd_45972_validation.xml.gz | 17.2 KB | Display | |
| Data in CIF | emd_45972_validation.cif.gz | 20.9 KB | Display | |
| Arichive directory | https://ftp.pdbj.org/pub/emdb/validation_reports/EMD-45972 ftp://ftp.pdbj.org/pub/emdb/validation_reports/EMD-45972 | HTTPS FTP |
-Related structure data
| Related structure data | ![]() 9cwrMC ![]() 9cwpC ![]() 9cwqC C: citing same article ( M: atomic model generated by this map |
|---|
-
Links
| EMDB pages | EMDB (EBI/PDBe) / EMDataResource |
|---|
-
Map
| File | Download / File: emd_45972.map.gz / Format: CCP4 / Size: 512 MB / Type: IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | sharpened map | ||||||||||||||||||||||||||||||||||||
| Projections & slices | Image control
Images are generated by Spider. | ||||||||||||||||||||||||||||||||||||
| Voxel size | X=Y=Z: 1 Å | ||||||||||||||||||||||||||||||||||||
| Density |
| ||||||||||||||||||||||||||||||||||||
| Symmetry | Space group: 1 | ||||||||||||||||||||||||||||||||||||
| Details | EMDB XML:
|
-Supplemental data
-Additional map: unsharpened map
| File | emd_45972_additional_1.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | unsharpened map | ||||||||||||
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-Half map: #2
| File | emd_45972_half_map_1.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-Half map: #1
| File | emd_45972_half_map_2.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-
Sample components
-Entire : SARS-CoV-2 BA.2.86 Spike trimer in complex with TRI2-2 minibinder
| Entire | Name: SARS-CoV-2 BA.2.86 Spike trimer in complex with TRI2-2 minibinder |
|---|---|
| Components |
|
-Supramolecule #1: SARS-CoV-2 BA.2.86 Spike trimer in complex with TRI2-2 minibinder
| Supramolecule | Name: SARS-CoV-2 BA.2.86 Spike trimer in complex with TRI2-2 minibinder type: complex / ID: 1 / Parent: 0 / Macromolecule list: #1-#2 |
|---|---|
| Source (natural) | Organism: Sarbecovirus sp. |
-Macromolecule #1: BA.2.86 spike protein
| Macromolecule | Name: BA.2.86 spike protein / type: protein_or_peptide / ID: 1 / Number of copies: 3 / Enantiomer: LEVO |
|---|---|
| Source (natural) | Organism: ![]() |
| Molecular weight | Theoretical: 141.503062 KDa |
| Recombinant expression | Organism: Homo sapiens (human) |
| Sequence | String: MFVFLVLLPL VSSQCVMPLF NLITTTQSYT NSFTRGVYYP DKVFRSSVLH LTQDLFLPFF SNVTWFHAIS GTNGTKRFDN PVLPFNDGV YFASTEKSNI IRGWIFGTTL DSKTQSLLIV NNATNVFIKV CEFQFCNDPF LDVYHKNNKS WMESESGVYS S ANNCTFEY ...String: MFVFLVLLPL VSSQCVMPLF NLITTTQSYT NSFTRGVYYP DKVFRSSVLH LTQDLFLPFF SNVTWFHAIS GTNGTKRFDN PVLPFNDGV YFASTEKSNI IRGWIFGTTL DSKTQSLLIV NNATNVFIKV CEFQFCNDPF LDVYHKNNKS WMESESGVYS S ANNCTFEY VSQPFLMDLE GKQGNFKNLR EFVFKNIDGY FKIYSKHTPI IGRDFPQGFS ALEPLVDLPI GINITRFQTL LA LNRSYLT PGDSSSGWTA GAADYYVGYL QPRTFLLKYN ENGTITDAVD CALDPLSETK CTLKSFTVEK GIYQTSNFRV QPT ESIVRF PNVTNLCPFH EVFNATRFAS VYAWNRTRIS NCVADYSVLY NFAPFFAFKC YGVSPTKLND LCFTNVYADS FVIK GNEVS QIAPGQTGNI ADYNYKLPDD FTGCVIAWNS NKLDSKHSGN YDYWYRLFRK SKLKPFERDI STEIYQAGNK PCKGK GPNC YFPLQSYGFR PTYGVGHQPY RVVVLSFELL HAPATVCGPK KSTNLVKNKC VNFNFNGLTG TGVLTKSNKK FLPFQQ FGR DIVDTTDAVR DPQTLEILDI TPCSFGGVSV ITPGTNTSNQ VAVLYQGVNC TEVSVAIHAD QLTPTWRVYS TGSNVFQ TR AGCLIGAEYV NNSYECDIPI GAGVCASYQT QTKSRGSASS VASQSIIAYT MSLGAENSVA YSNNSIAIPT NFTISVTT E ILPVSMTKTS VDCTMYICGD STECSNLLLQ YGSFCTQLKR ALTGIAVEQD KNTQEVFAQV KQIYKTPPIK YFGGFNFSQ ILPDPSKPSK RSPIEDLLFN KVTLADAGFI KQYGDCLGDI AARDLICAQK FNGLTVLPPL LTDEMIAQYT SALLAGTITS GWTFGAGPA LQIPFPMQMA YRFNGIGVTQ NVLYENQKLI ANQFNSAIGK IQDSLFSTPS ALGKLQDVVN HNAQALNTLV K QLSSKFGA ISSVLNDILS RLDPPEAEVQ IDRLITGRLQ SLQTYVTQQL IRAAEIRASA NLAATKMSEC VLGQSKRVDF CG KGYHLMS FPQSAPHGVV FLHVTYVPAQ EKNFTTAPAI CHDGKAHFPR EGVFVSNGTH WFVTQRNFYE PQIITTDNTF VSG NCDVVI GIVNNTVYDP LQLELDSFKE ELDKYFKNHT SPDVDLGDIS GINASVVNIQ KEIDRLNEVA KNLNESLIDL QELG KYEQG SGYIPEAPRD GQAYVRKDGE WVLLSTFLGR SLEVLFQGPG SGGLNDIFEA QKIEWHEGSG HHHHHHHH |
-Macromolecule #2: TRI2-2 minibinder
| Macromolecule | Name: TRI2-2 minibinder / type: protein_or_peptide / ID: 2 / Number of copies: 3 / Enantiomer: LEVO |
|---|---|
| Source (natural) | Organism: synthetic construct (others) |
| Molecular weight | Theoretical: 17.565787 KDa |
| Recombinant expression | Organism: ![]() |
| Sequence | String: ELEEQVMHVL DQVSELAHEL LHKLTGEELE RAAYFNWWAT EMMLELIKSD DEREIREIEE EARRILEHLE ELARKGGSEA LEELEKALR ELKKSTDELE RSTEELEKNP SEDALVENNR LIVENNKIIV EVLRIIAKVL KLEHHHHHH |
-Macromolecule #4: 2-acetamido-2-deoxy-beta-D-glucopyranose
| Macromolecule | Name: 2-acetamido-2-deoxy-beta-D-glucopyranose / type: ligand / ID: 4 / Number of copies: 26 / Formula: NAG |
|---|---|
| Molecular weight | Theoretical: 221.208 Da |
| Chemical component information | ![]() ChemComp-NAG: |
-Macromolecule #5: water
| Macromolecule | Name: water / type: ligand / ID: 5 / Number of copies: 667 / Formula: HOH |
|---|---|
| Molecular weight | Theoretical: 18.015 Da |
| Chemical component information | ![]() ChemComp-HOH: |
-Experimental details
-Structure determination
| Method | cryo EM |
|---|---|
Processing | single particle reconstruction |
| Aggregation state | particle |
-
Sample preparation
| Buffer | pH: 8 |
|---|---|
| Vitrification | Cryogen name: ETHANE |
-
Electron microscopy
| Microscope | TFS KRIOS |
|---|---|
| Image recording | Film or detector model: GATAN K3 (6k x 4k) / Average electron dose: 53.25 e/Å2 |
| Electron beam | Acceleration voltage: 300 kV / Electron source: FIELD EMISSION GUN |
| Electron optics | Illumination mode: FLOOD BEAM / Imaging mode: BRIGHT FIELD / Nominal defocus max: 1.8 µm / Nominal defocus min: 0.8 µm |
| Experimental equipment | ![]() Model: Titan Krios / Image courtesy: FEI Company |
Movie
Controller
About Yorodumi



Keywords
Sarbecovirus sp.
Authors
United States, 1 items
Citation




Z (Sec.)
Y (Row.)
X (Col.)












































Homo sapiens (human)


Processing
FIELD EMISSION GUN
